Clinical trial
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
NCT00005028 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00005028 |
|---|---|
| Title | Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer |
| Official title | Phase II Study of Weekly Paclitaxel and Bryostatin-1 in Hormone Refractory Prostate Cancer |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | bryostatin 1, paclitaxel |
| Enrollment | 46 |
| Start date | May 1, 2000 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Mar 7, 2003 |
| Last update posted | Nov 4, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: